Gossamer Bio, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Opaleye Management Inc., Opaleye L.P., and James Silverman have jointly filed a Schedule 13G, reporting beneficial ownership of over 5% of Gossamer Bio, Inc. common stock.
NASDAQ
DeepCurrents Investment Group LLC and affiliates have reported a 7.7% beneficial ownership stake in Gossamer Bio, Inc. via a Schedule 13G filing.
NASDAQ
683 Capital Management, LLC and Ari Zweiman have reported a 9.99% beneficial ownership stake in Gossamer Bio, Inc. as of June 11, 2026.
NASDAQ
Context Capital Management, LLC and its affiliates have reported beneficial ownership of 48,835,788 shares, representing 9.9% of the outstanding common stock of Gossamer Bio, Inc.
NASDAQ
Octagon Capital Advisors LP, along with affiliated entities and Ting Jia, has reported beneficial ownership of 8,976,054 shares, representing 3.8% of Gossamer Bio, Inc.'s common stock.
NASDAQ
The Vanguard Group has filed an Amendment No. 6 to Schedule 13G, reporting zero beneficial ownership in Gossamer Bio Inc. Common Stock following an internal realignment.
NASDAQ
683 Capital Management, LLC and its affiliates have disclosed a 3.9% beneficial ownership stake in Gossamer Bio, Inc., comprising common stock and exercisable warrants.
NASDAQ
683 Capital Management, LLC and its affiliates have reported a 5.23% beneficial ownership stake in Gossamer Bio, Inc., including common stock and exercisable warrants.
NASDAQ
SCHEDULE 13G/A: BlackRock Boosts Stake in Gossamer Bio to 6.5%
BlackRock, Inc. has reported a beneficial ownership of 6.5% in Gossamer Bio, Inc. common stock as of December 31, 2025.
NASDAQ
The Vanguard Group has reported a passive ownership stake of 5.02% in Gossamer Bio Inc., holding over 11.4 million shares of common stock.
NASDAQ
SCHEDULE 13G: BlackRock Discloses 5.3% Passive Stake in Gossamer Bio
BlackRock, Inc. has filed a Schedule 13G, reporting a 5.3% beneficial ownership stake in Gossamer Bio, Inc. as of June 30, 2025.
NASDAQ
Multiple Invus-affiliated entities and Raymond Debbane have filed an amended Schedule 13G, disclosing a collective beneficial ownership of 2.8% in Gossamer Bio, Inc. as of December 31, 2024.
NASDAQ
Octagon Capital Advisors LP, Octagon Investments Master Fund LP, and Ting Jia have jointly reported a passive beneficial ownership of 8.6% in Gossamer Bio, Inc.'s common stock as of December 31, 2024.
NASDAQ
The Vanguard Group has filed an Amendment No. 5 to its Schedule 13G, disclosing a 4.42% beneficial ownership stake in Gossamer Bio Inc. as of December 31, 2024.